CLS vs. ANAB
CLS (Celestica Inc.) and ANAB (AnaptysBio, Inc.) are both stocks. CLS operates in Electronic Components (Technology), while ANAB operates in Biotechnology (Healthcare). Over the past 5 years, CLS returned 116.26%/yr vs 28.21%/yr for ANAB. At a 0.18 correlation, their price movements are largely independent.
Performance
CLS vs. ANAB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLS achieves a 32.99% return, which is significantly lower than ANAB's 73.48% return.
CLS
- 1D
- 1.88%
- 1M
- 5.52%
- YTD
- 32.99%
- 6M
- 28.26%
- 1Y
- 200.71%
- 3Y*
- 207.28%
- 5Y*
- 116.26%
- 10Y*
- 43.71%
ANAB
- 1D
- 3.37%
- 1M
- -10.55%
- YTD
- 73.48%
- 6M
- 87.15%
- 1Y
- 259.27%
- 3Y*
- 64.14%
- 5Y*
- 28.21%
- 10Y*
- —
CLS vs. ANAB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CLS Celestica Inc. | 32.99% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -16.32% | -16.76% |
ANAB AnaptysBio, Inc. | 73.48% | 266.16% | -38.19% | -30.88% | -10.82% | 61.63% | 32.31% | -74.53% | -36.67% | 529.50% |
Correlation
The correlation between CLS and ANAB is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jan 26, 2017 | 0.18 |
Fundamentals
CLS:
$45.48B
ANAB:
$1.61B
CLS:
$8.28
ANAB:
-$0.91
CLS:
3.30
ANAB:
7.11
CLS:
21.68
ANAB:
126.20
CLS:
$13.81B
ANAB:
$232.39M
CLS:
$1.60B
ANAB:
$245.59M
CLS:
$1.32B
ANAB:
$52.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLS vs. ANAB — Risk / Return Rank
CLS
ANAB
CLS vs. ANAB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Celestica Inc. (CLS) and AnaptysBio, Inc. (ANAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLS | ANAB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.02 | ||
| Sortino ratioReturn per unit of downside risk | -1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.53 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 6.91 | 9.28 | -2.37 |
| Martin ratioReturn relative to average drawdown | 16.83 | 22.38 | -5.55 |
Loading charts...
Drawdowns
CLS vs. ANAB - Drawdown Comparison
The maximum CLS drawdown since its inception was -96.93%, which is greater than ANAB's maximum drawdown of -92.08%. Use the drawdown chart below to compare losses from any high point for CLS and ANAB.
Loading charts...
Drawdown Indicators
| CLS | ANAB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.93% | -92.08% | -4.85% |
Max Drawdown (1Y)Largest decline over 1 year | -29.24% | -28.15% | -1.09% |
Max Drawdown (3Y)Largest decline over 3 years | -53.96% | -69.32% | +15.36% |
Max Drawdown (5Y)Largest decline over 5 years | -53.96% | -69.32% | +15.36% |
Max Drawdown (10Y)Largest decline over 10 years | -80.60% | — | — |
Current DrawdownCurrent decline from peak | -16.78% | -34.57% | +17.79% |
Average DrawdownAverage peak-to-trough decline | -73.31% | -64.64% | -8.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.98% | 11.64% | +0.34% |
Volatility
CLS vs. ANAB - Volatility Comparison
Celestica Inc. (CLS) has a higher volatility of 27.54% compared to AnaptysBio, Inc. (ANAB) at 12.40%. This indicates that CLS's price experiences larger fluctuations and is considered to be riskier than ANAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLS | ANAB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.54% | 12.40% | +15.14% |
Volatility (6M)Calculated over the trailing 6-month period | 55.42% | 46.31% | +9.11% |
Volatility (1Y)Calculated over the trailing 1-year period | 72.65% | 68.78% | +3.87% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 57.70% | 65.31% | -7.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 49.97% | 75.44% | -25.47% |
Dividends
CLS vs. ANAB - Dividend Comparison
Neither CLS nor ANAB has paid dividends to shareholders.
Financials
CLS vs. ANAB - Financials Comparison
This section allows you to compare key financial metrics between Celestica Inc. and AnaptysBio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CLS and ANAB have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (27.54%) compared to ANAB (12.40%). In terms of maximum drawdown, CLS dropped -96.93% vs ANAB's -92.08%.
ANAB currently has the higher Sharpe Ratio (3.80 vs 2.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLS and ANAB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer